Trial Profile

Food-effect Study of Weekly Administration of (bi-)Daily Oral Docetaxel (ModraDoc006) in Combination With Ritonavir

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 22 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Docetaxel/ritonavir (Primary) ; Ritonavir (Primary)
Indications Advanced breast cancer; Anal cancer; Bladder cancer; Carcinoma; Cervical cancer; Gastric cancer; Head and neck cancer; Neuroendocrine carcinoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Prostate cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
Focus Pharmacokinetics
Sponsors Modra Pharmaceuticals

Most Recent Events

19 Jan 2021 Status changed from active, no longer recruiting to completed as per resultspublished in the Drugs in R and D.
19 Jan 2021 Results published in the Drugs in R and D.
25 Mar 2019 Planned End Date changed from 1 Feb 2019 to 1 Jul 2019.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com